Delivery Order SPE2DB22D2206-SPE2DB25FJN07
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a Delivery Order valued at $9,586.26 by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Myrbetriq ER 25 mg tablets (90-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 13, 2025, and represents a non-set-aside procurement. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp has been awarded a delivery order from the Defense Logistics Agency for $12,459.55 to supply Myrbetriq ER 50 mg tablets in a 90-count quantity. The award was issued on July 30, 2025, with an ultimate completion date of July 31, 2025, and utilizes firm fixed pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order represents a competitive...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $28,170.24 by the Defense Logistics Agency (DLA) for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 1, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $1,248.63 by the Defense Logistics Agency on July 25, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count packaging). The contract employs firm fixed pricing and carries an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside delivery order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, which serves as the company's corporate office and primary distribution hub...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for Myrbetriq ER 25 mg tablets (90-count supply) with a contract ceiling value of $7,101.28. The award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order valued at $2,729.22 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count supply). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 1, 2025, and represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $8,784.72 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. No set-aside...
- This is a $23,017.73 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Myrbetriq ER 50 mg tablets. The contract has an ultimate completion date of May 21, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $36,113.23 on July 29, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by July 30, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract valued at $8,276.16. The award was made on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJN07Delivery Order
AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency (DLA) valued at $8,524.87 for Myrbetriq ER 50 mg tablets (90-count supply). The contract is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a non-set-aside procurement. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December 2026 that supplies medications and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical federal vendor for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive pharmaceutical portfolio encompasses brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains, demonstrating its capability to fulfill diverse federal medical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 8/20/25 |